Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016


  • Products Id :- GMDHC0511TDB
  • |
  • Pages: 76
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A)

- The report reviews Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics and enlists all their major and minor projects

- The report assesses Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Overview 7

Therapeutics Development 8

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Stage of Development 8

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Therapy Area 9

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Indication 10

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Companies 13

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Companies Involved in Therapeutics Development 21

AbbVie Inc 21

Abeome Corporation 22

Affibody AB 23

Cell Medica Limited 24

Eli Lilly and Company 25

Johnson & Johnson 26

Merck KGaA 27

Novartis AG 28

Orega Biotech SAS 29

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Drug Profiles 30

ABT-122 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

ABY-035 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CNTO-6785 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

DLX-2882 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

DLX-2907 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

DLX-2909 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

ixekizumab - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

M-1095 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Monoclonal Antibody to Inhibit IL-17A for Psoriasis and Inflammation - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

OREG-203 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

secukinumab - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Dormant Projects 60

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Discontinued Products 61

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Featured News & Press Releases 62

Aug 04, 2016: NICE draft guidance recommends new drug for people with ankylosing spondylitis 62

Jun 21, 2016: Health Canada approval of Taltz (ixekizumab) Brings Targeted Therapy to Canadians Living with Moderate-to-Severe Plaque Psoriasis 62

Jun 09, 2016: New drug clears psoriasis in clinical trials 64

Jun 08, 2016: Studies Demonstrate Lilly's Taltz (Ixekizumab) Maintained Or Achieved High Levels Of Skin Clearance For Patients With Moderate-To-Severe Plaque Psoriasis Through 60 Weeks: Results Published In The New England Journal Of Medicine 65

Jun 08, 2016: Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 66

Jun 07, 2016: Eli Lilly and Company Announces Data on Ixekizumab At Annual European Congress Of Rheumatology 67

Jun 07, 2016: Tampa Dermatologist Launches Clinical Trial for Psoriatic Arthritis Patients 68

Jun 02, 2016: AbbVie Announces Presentation on ABT-122 at the Annual European Congress of Rheumatology 68

May 04, 2016: Affibody Announces Initial Results from a Phase I Study of ABY-035 69

May 02, 2016: Lilly's Taltz (Ixekizumab) Now Available In The U.S. For The Treatment Of Moderate-To-Severe Plaque Psoriasis 69

Apr 27, 2016: COSENTYX - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada 71

Apr 26, 2016: Lilly announces European Commission approval for plaque psoriasis drug 71

Apr 23, 2016: OptiMed Specialty Pharmacy to Distribute Cosentyx 72

Apr 05, 2016: Diplomat Announces TALTZ Availability for the Treatment of Plaque Psoriasis 72

Mar 22, 2016: Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Moderate-To-Severe Plaque Psoriasis 73

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 17

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 19

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 16

Number of Products by Stage and Route of Administration, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 20

Pipeline by AbbVie Inc, H2 2016 21

Pipeline by Abeome Corporation, H2 2016 22

Pipeline by Affibody AB, H2 2016 23

Pipeline by Cell Medica Limited, H2 2016 24

Pipeline by Eli Lilly and Company, H2 2016 25

Pipeline by Johnson & Johnson, H2 2016 26

Pipeline by Merck KGaA, H2 2016 27

Pipeline by Novartis AG, H2 2016 28

Pipeline by Orega Biotech SAS, H2 2016 29

Dormant Projects, H2 2016 60

Discontinued Products, H2 2016 61

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc

Abeome Corporation

Affibody AB

Cell Medica Limited

Eli Lilly and Company

Johnson & Johnson

Merck KGaA

Novartis AG

Orega Biotech SAS

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Therapeutic Products under Development, Key Players in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Therapeutics, Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Pipeline Overview, Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Pipeline, Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Pipeline Assessment

select a license

Single User License
USD 3500 INR 224070
Site License
USD 7000 INR 448140
Corporate User License
USD 10500 INR 672210

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com